The Law Offices of Frank R. Cruz Announces Investigation of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (IVVD) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (“Adagio” or the “Company”) (NASDAQ: IVVD) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On December 14, 2021, Adagio disclosed that its COVID-19 treatment and prevention product, ADG20, was 300 times less effective at neutralizing the Omicron variant than it was against other variants, despite previous assurance of the efficacy against Omicron.

On this news, Adagio’s stock price fell $27, or 78.8%, to close at $7.26 per share on December 14, 2021, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Adagio securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [e-mail], or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.